These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 8946904)

  • 1. Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan.
    Kessler DA; Hass AE; Feiden KL; Lumpkin M; Temple R
    JAMA; 1996 Dec; 276(22):1826-31. PubMed ID: 8946904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
    Rawson NS
    CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delays in psychiatric drug development in Japan.
    Shimazawa R; Kusumi I; Ikeda M
    J Clin Pharm Ther; 2012 Jun; 37(3):348-51. PubMed ID: 22017294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI
    Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 6. Obtaining drugs from foreign markets.
    Shirk MB; Hale KN
    Am J Hosp Pharm; 1992 Nov; 49(11):2731-9. PubMed ID: 1471638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparative Study of the Market Configuration of the Japanese Pharmaceutical Market Using the Gini Coefficient and Herfindahl-Hirschman Index.
    Shibata S; Fukumoto D; Suzuki T; Ozaki K
    Ther Innov Regul Sci; 2020 Sep; 54(5):1047-1055. PubMed ID: 31989539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food and Drug Administration Drug Approval Process: A History and Overview.
    Williams CT
    Nurs Clin North Am; 2016 Mar; 51(1):1-11. PubMed ID: 26897420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1992 Le Tourneau Award. Problems with pharmaceutical regulation in the United States. Drug lag and orphan drugs.
    Henry V
    J Leg Med; 1993 Dec; 14(4):617-39. PubMed ID: 8308452
    [No Abstract]   [Full Text] [Related]  

  • 10. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sanofi Pharmaceuticals, Inc., et al.; withdrawal of approval of 21 new drug applications and 62 abbreviated new drug applications--FDA. Notice.
    Fed Regist; 1998 May; 63(91):26191-3. PubMed ID: 10179336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whatever happened to user fees and the FDA's promise to expedite new drug approvals?
    Gatty B
    Hosp Formul; 1993 Jul; 28(7):656, 655. PubMed ID: 10127048
    [No Abstract]   [Full Text] [Related]  

  • 14. Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made?
    Rawson NS
    Clin Ther; 2003 Apr; 25(4):1230-47. PubMed ID: 12809970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 16. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
    Schultheis LW; Rappaport BA
    Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
    [No Abstract]   [Full Text] [Related]  

  • 17. Obstacles and opportunities in new drug development.
    Kaitin KI
    Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685
    [No Abstract]   [Full Text] [Related]  

  • 18. Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?
    Arnold DG; Troyer JL
    J Health Polit Policy Law; 2016 Apr; 41(2):157-79. PubMed ID: 26732315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug pipeline: 3Q15.
    DeFrancesco L
    Nat Biotechnol; 2015 Nov; 33(11):1126. PubMed ID: 26544135
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.